Document Detail


The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.
MedLine Citation:
PMID:  20021295     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE TO THE FIELD: Acamprosate, marketed under the brand name Campral, (Forest Pharmaceuticals, Inc., Saint Louis, MO, USA; Merck Sante s.a.s., Lyon, France) is an orally administered drug approved in the US and throughout much of the world for treating alcohol dependence. Its safety and efficacy have been demonstrated in a number of clinical trials worldwide and as with all pharmacotherapies for alcoholism, it is used in conjunction with psychosocial interventions.
AREAS COVERED IN THIS REVIEW: This article reviews the mechanism of action, clinical efficacy and safety of acamprosate in Phase I, II and III randomized controlled trials involving healthy and alcohol-dependent populations using published reports from 1984 to 2009.
WHAT THE READER WILL GAIN: This review provides an update of the mechanism of action and the safety and efficacy profile of acamprosate.
TAKE HOME MESSAGE: Acamprosate appears to act centrally to restore the normal activity of glutamatergic neurotransmission altered by chronic alcohol exposure. Acamprosate's excellent safety profile along with several pharmacokinetic and pharmacodynamic characteristics make it well suited for treating a broad population of alcohol-dependent patients.
Authors:
Barbara J Mason; Charles J Heyser
Related Documents :
16917685 - Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: ...
18978635 - Efficacy of outpatient aftercare for adolescents with alcohol use disorders: a randomiz...
18705645 - Autonomous motivation, controlled motivation, and goal progress.
18068515 - Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-d...
2963205 - Climacteric symptoms after oral and percutaneous hormone replacement therapy.
21455355 - Lunar phase and psychiatric illness in goa.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  9     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-21     Completed Date:  2010-03-04     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  177-88     Citation Subset:  IM    
Affiliation:
Pearson Center for Alcoholism and Addiction Research, The Scripps Research Institute, 10550 North Torrey Pines Road, TPC-5, La Jolla, CA 92037, USA. mason@scripps.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alcohol Deterrents / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Alcoholism / drug therapy*
Animals
Cognition / drug effects
Diarrhea / chemically induced
Disease Models, Animal
Drug Interactions
Humans
Randomized Controlled Trials as Topic
Receptors, Glutamate / drug effects
Sleep Initiation and Maintenance Disorders / chemically induced,  drug therapy
Synaptic Transmission / drug effects*
Taurine / adverse effects,  analogs & derivatives*,  pharmacology,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Alcohol Deterrents; 0/Receptors, Glutamate; 107-35-7/Taurine; N4K14YGM3J/acamprosate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's ...
Next Document:  Gonadal dysfunction and pelvic sonographic findings in females with thalassaemia major.